Onconova Therapeutics (NASDAQ: ONTX) Decreased to Hold at Zacks Investment Research

NASDAQ: ONTX was reduced by  Zacks Research  from a “acquire” score to a “hold” rating in a research note released to investors on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical business. It concentrates on finding and creating small molecule medicine prospects to deal with cancer cells. The Business‘s products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and also Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

A number of other equities research analysts also lately discussed the business. Noble Financial reissued a “purchase” score as well as provided a $11.00 cost purpose on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 as well as established a “purchase” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. Business has a 50 day relocating typical cost of $2.90 as well as a two-hundred day relocating ordinary price of $4.16. The company has a market cap of $46.76 million, a P/E proportion of -1.82 as well as a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly earnings outcomes on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) earnings per share for the quarter, covering experts’ consensus estimates of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% as well as an unfavorable net margin of 8,294.27%. The firm had profits of $0.06 million throughout the quarter, compared to the agreement quote of $0.06 million. Throughout the exact same quarter in the previous year, the company published ($ 0.45) EPS. En masse, research experts anticipate that Onconova Therapeutics will publish -1.18 EPS for the current year.

A variety of hedge funds have recently dealt shares of ONTX. GSA Funding Partners LLP purchased a brand-new position in Onconova Therapeutics during the 3rd quarter worth $922,000. Hudson Bay Capital Monitoring LP purchased a new position in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC acquired a brand-new setting in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC purchased a new setting in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Finally, Dimensional Fund Advisors LP bought a new placement in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds as well as other institutional investors possess 13.36% of the firm’s stock.

Concerning Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which takes part in the identification and also advancement of oncology therapeutics. It concentrates on discovering and establishing tiny particle drug candidates to treat cancer. The firm was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Get a totally free duplicate of the Zacks research report on Onconova Therapeutics (ONTX).

For more details concerning research offerings from Zacks Investment Research, browse through Zacks.com.

This instantaneous information alert was created by narrative science innovation and economic information from Market in order to provide readers with the fastest and most precise reporting. This tale was reviewed by Market’s editorial team before magazine. 

 

SHOULD YOU INVEST $1,000 IN ONCONOVA THERAPEUTICS RIGHT NOW?

Before you think about Onconova Therapeutics, you’ll want to hear this.

Market tracks Wall Street’s premier and finest carrying out research analysts and the stocks they recommend to their customers each day. Market has actually determined the five stocks that top analysts are silently whispering to their customers to buy now prior to the broader market catches on … as well as Onconova Therapeutics wasn’t on the list.

While Onconova Therapeutics currently has a “Buy” ranking among experts, top-rated experts think these 5 stocks are better purchases.